|Segment||Equity: Global Ex-U.S. - Total Market Growth||Equity: Global Biotech|
|Management Style||passive (index-based)||active|
The Fund seeks long-term capital appreciation above international benchmarks such as the MSCI EAFE Index and the BNY Mellon Classic ADR Index. The Fund selects a portfolio of U.S. traded securities of non-U.S. organizations, most often American Depositary Receipts (ADRs), included in the BNY Mellon Classic ADR Index.
AADR performance & returns
Top 10 Holdings (45.63% of Total Assets)
|NICE Ltd ADR||NICE||6.54%|
|Gold Fields Ltd ADR||GFI.JO||5.86%|
|argenx SE ADR||ARGX||5.52%|
|Anglogold Ashanti Ltd ADR||AU.JO||3.64%|
|TAL Education Group ADR||TAL||3.63%|
|ASML Holding NV ADR||ASML||3.59%|
|ZTO Express (Cayman) Inc ADR||ZTO||3.35%|
|Sibanye Stillwater Ltd ADR||SBSW.JO||3.21%|
|LVMH Moet Hennessy Louis Vuitton SE ADR||LVMUY.PA||3.08%|
AADR prosNone that we could think of.
AADR consNone that we could think of.
Other relevant AADR comparisons
You may also want to check out the following AADR comparisons that investors often look for on Finny
The Fund seeks long-term growth of capital. The Fund is an actively-managed exchange-traded fund that will invest under normal circumstances primarily in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary.
ARKG performance & returns
Top 10 Holdings (52.77% of Total Assets)
|CRISPR Therapeutics AG||CRSP||8.44%|
|Pacific Biosciences of California Inc||PACB||7.19%|
|Arcturus Therapeutics Holdings Inc||ARCT||5.75%|
|Twist Bioscience Corp||TWST||4.61%|
|Iovance Biotherapeutics Inc||IOVA||3.76%|
|Exact Sciences Corp||EXAS||3.41%|
|Seres Therapeutics Inc||MCRB||3.38%|
The following are ARKG strengths from our perspective:
- ARKG 3-year return is 34.54%, which is higher than the 3-year return of the benchmark index (MSCI ACWI NR USD), 8.21%.
- ARKG 5-year return is 24.54%, which is higher than the 5-year return of the benchmark index (MSCI ACWI NR USD), 10.45%.
The following are ARKG weaknesses from our perspective:
- ARKG net assets are $886.97 million. This fund is not a popular choice with retail investors.
- ARKG expense ratio is 0.75%, which is not negligible. Is the fund expensive to you, and does it align to your investment strategy?
Other relevant ARKG comparisons
You may also want to check out the following ARKG comparisons that investors often look for on Finny